He said not much has changed in the published version.
The Elgazzar study was one of the the largest and most promising showing the drug may help Covid patients, and has often been cited by proponents of the drug as evidence of its effectiveness.
Average patient age was 62.
He also identified the duplication of patient deaths and data.
Plus, these results show a probability of 75% that patients on ivermectin did better than patients on placebo.
On the other hand, the upside is significant — possible lives saved.